The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
Open accessAbstract
Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. Hence, we compared and ranked the efficacy and tolerability of these available drugs. We searched PubMed, the Cochrane Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) published from database inception to July 21, 2017. The primary outcomes were the mean overall changes in cognitive function and responders who had any adverse events. We conducted a random-effects network meta-analysis. Forty-one RCTs were included in this study. Compared with placebo, galantamine 32 mg daily (standardized mean difference – 0.51, 95% credible interval – 0.67 to − 0.35), galantamine 24 mg daily (− 0.50, − 0.61 to − 0.40), and donepezil 10 mg daily (− 0.40, − 0.51 to − 0.29) were probably the most effective agents on cognition for mild to moderate AD, and memantine 20 mg combined with donepezil 10 mg (0.76, 0.39 to 1.11) was recommended for moderate to severe patients. Memantine showed the best profile of acceptability. Rivastigmine transdermal 15-cm 2 patch was the best optional treatment both in function and global changes. None of the medicines was likely to improve neuropsychiatric symptoms through this analysis. Pharmacological interventions have beneficial effects on cognition, function, and global changes, but not on neuropsychiatric symptoms, through current network meta-analysis. The choice of drugs may mainly depend on the disease severity and clinical symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cholinesterase inhibitors provide only symptomatic relief of behavioral deficits without modifying the complex pathologies in mild to moderate Alzheimer's disease patients.
“Cholinesterase inhibitors provide only symptomatic relief of behavioral deficits without modifying the complex pathologies in mild to moderate AD patients [20].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [20]
Memantine is mainly recommended for moderate to severe Alzheimer's disease cases.
“However, memantine is mainly recommended for moderate to severe AD cases [20].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
(2015) · HAL · Cited by 2,238
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Intention-to-Treat Analysis: Implications for Quantitative and Qualitative Research
NEWELL, D. J. (1992) · International Journal of Epidemiology · doi:10.1093/ije/21.5.837 · Cited by 715
Evaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576
Tan, C.-C., Yu, J.-T., Wang, H.-F., Tan, M.-S., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132690 · Cited by 484
Self-citationBond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A. H., Moxham, T., Davis, S., Thokala, P., Wailoo, A., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16210 · Cited by 308
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 307
Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis
Kishi, T., Matsunaga, S., Oya, K., Nomura, I., Ikuta, T., & Iwata, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170424 · Cited by 256
Tan, M., Yu, J., Tan, C., Wang, H.-F., Meng, X., Wang, C., Jiang, T., Zhu, X., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140837 · Cited by 253
Self-citationFink, H. A., Jutkowitz, E., McCarten, J. R., Hemmy, L. S., Butler, M., Davila, H. W., Ratner, E. R., Calvert, C., Barclay, T. R., Brasure, M., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1529 · Cited by 205
Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials
Trinquart, L., Attiche, N., Bafeta, A., Porcher, R., & Ravaud, P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2521 · Cited by 202
Howard, R. J., McShane, R. H., Lindesay, J. E. B., Ritchie, C. W., Baldwin, A., Barber, R., Burns, A. S., Dening, T., Findlay, D. M., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 171
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
Khoury, R., Rajamanickam, J., & Grossberg, G. T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617750555 · Cited by 156
Wang, J., Yu, J., Wang, H.-F., Meng, X., Wang, C., Tan, C., & Tan, L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308112 · Cited by 151
Self-citationSchmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Donegan, K. L., Fox, N. C., Black, N. A., Livingston, G., Banerjee, S., & Burns, A. S. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30031-2 · Cited by 139
Gauthier, S. G., & Molinuevo, J. L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.11.005 · Cited by 111
Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance
Lee, J., Jeong, S., Kim, B. C., Park, K. W., & Dash, A. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12386 · Cited by 77
Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease
Getsios, D., Blume, S., Ishak, K. J., & Maclaine, G. D. H. (2010) · PharmacoEconomics · doi:10.2165/11531870-000000000-00000 · Cited by 76
Pharmacokinetic rationale for the rivastigmine patch
Cummings, J. L., Lefèvre, G. Y., Small, G. W., & Appel‐Dingemanse, S. (2007) · Neurology · doi:10.1212/01.wnl.0000281846.40390.50 · Cited by 72
Cummings, J. L., Geldmacher, D., Farlow, M. R., Sabbagh, M. N., Christensen, D. D., & Betz, P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12076 · Cited by 64
Knapp, M. R. J., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C. G., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4583 · Cited by 63
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Sahakian, B. J., & Morein‐Zamir, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00004-8 · Cited by 55
Trinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
Tricco, A. C., vanderVaart, S., Soobiah, C., Lillie, E., Perrier, L., Chen, M. H., Hemmelgarn, B. R., Majumdar, S. R., & Straus, S. E. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-31 · Cited by 30
on behalf of the Registry of Dementias of Girona Study Group (ReDeGi Study Group), Calvó-Perxas, L., Turró-Garriga, O., Vilalta-Franch, J., Lozano-Gallego, M., de Eugenio, R., Márquez, F., Carmona, O., Gich, J., Manzano, A., et al. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0446-x · Cited by 30
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215431 · Cited by 28
Frampton, J. E. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0197-x · Cited by 13
Sabbagh, M. N., Han, S., Kim, S., Na, H. R., Lee, J., Kandiah, N., Phanthumchinda, K., Suthisisang, C. C., Senanarong, V., Pai, M., et al. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000448214 · Cited by 10
Flagged first, then by citations
Research works printed but not linked: 1
- NICE. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Care Excellence; 2011.
Cited by
Sorted by citations
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 845
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R.-N., Bild, V., Chiriac, S. I. B., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 307
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 262
Gąsiorowska, A., Wydrych, M., Drapich, P., Zadrożny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 199
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
Vecchio, I., Sorrentino, L., Paoletti, A., Marra, R., & Arbitrio, M. (2021) · Journal of Central Nervous System Disease · doi:10.1177/11795735211029113 · Cited by 189
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165
Acetylcholine bidirectionally regulates learning and memory
Huang, Q., Liao, C., Ge, F., Ao, J., & Liu, T. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100002 · Cited by 172
Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same Disease?
Mihevc, S. P., & Majdič, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00604 · Cited by 152
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.01.005 · Cited by 132
Moss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 134
Treatment for Alzheimer's disease
Fox, N. C., Belder, C. R. S., Ballard, C. G., Kales, H. C., Mummery, C. J., Caramelli, P., Ciccarelli, O., Frederiksen, K. S., Gómez‐Isla, T., Ismail, Z., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01329-7 · Cited by 137
Tang, B., Wang, Y., & Ren, J. (2023) · Ibrain · doi:10.1002/ibra.12098 · Cited by 129
Mehla, J., Gupta, P., Pahuja, M., Diwan, D., & Diksha, D. (2020) · Brain Sciences · doi:10.3390/brainsci10120964 · Cited by 108
“However, memantine is mainly recommended for moderate to severe AD cases [20].”
BackgroundMemantine: Updating a rare success story in pro-cognitive therapeutics
Tari, P. K., Parsons, C. G., Collingridge, G. L., & Rammes, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109737 · Cited by 76
Zuin, M., Cherubini, A., Volpato, S., Ferrucci, L., & Zuliani, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-16476-w · Cited by 72
Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72
Iqbal, D., Rehman, M. T., Dukhyil, A. B., Rizvi, S. M. D., Ajmi, M. F. A., Alshehri, B., Banawas, S., Khan, M. S., Alturaiki, W., & Alsaweed, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090937 · Cited by 65
Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment
Pépin, M., Klimkowicz‐Mrowiec, A., Godefroy, O., Delgado, P., Carriazo, S. M., Ferreira, A. C., Golenia, A., Małyszko, J., Grodzicki, T. K., Giannakou, K., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15928 · Cited by 60
The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review
Fan, F., Liu, H., Shi, X., Ai, Y., Liu, Q., & Cheng, Y. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215423 · Cited by 54
Cacabelos, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779700 · Cited by 51
Choudhary, N., Dhingra, N., Gacem, A., Yadav, V. K., Verma, R. K., Choudhary, M., Bhardwaj, U., Chundawat, R. S., Alqahtani, M. S., Gaur, R. K., et al. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1193573 · Cited by 54
Boskovic, Z., Meier, S., Wang, Y., Milne, M., Onraet, T., Tedoldi, A., & Coulson, E. J. (2019) · Neuronal Signaling · doi:10.1042/ns20180066 · Cited by 48
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 47
Xue, D., Li, P. W. C., Yu, D. S. F., & Lin, R. S. Y. (2023) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2023.104592 · Cited by 48
Iqbal, D., Alsaweed, M., Jamal, Q. M. S., Asad, M. R., Rizvi, S. M. D., Rizvi, M. R., Albadrani, H. M., Hamed, M., Jahan, S., & Alyenbaawi, H. (2023) · Biomolecules · doi:10.3390/biom13111613 · Cited by 50
Zuliani, G., Zuin, M., Romagnoli, T., Polastri, M., Cervellati, C., & Brombo, G. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02675-6 · Cited by 41
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 43
Tseng, P., Zeng, B., Suen, M., Wu, Y., Correll, C. U., Zeng, B., Kuo, J. S., Chen, Y.-W., Chen, T., Tu, Y.-K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.017 · Cited by 39
Iqbal, D., Khan, M. S., Waiz, M., Rehman, M. T., Alaidarous, M., Jamal, A., Alothaim, A. S., Alajmi, M. F., Alshehri, B., Banawas, S., et al. (2021) · Cells · doi:10.3390/cells10123533 · Cited by 39
Gao, Y., Liu, Y., & Li, Y. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/176051 · Cited by 38
Millan, M. J., Dekeyne, A., Gobert, A., Brocco, M., la Cour, C. M., Ortuno, J., Watson, D. J., & Fone, K. C. F. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108099 · Cited by 38
The Impact of Cognitive Impairment on Cardiovascular Disease
Jamil, Y., Krishnaswami, A., Orkaby, A. R., Stimmel, M. B., Brown, C. H., Mecca, A. P., Forman, D. E., Rich, M. W., Nanna, M. G., & Damluji, A. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.057 · Cited by 39
Zhang, T., Liu, N., Cao, H., Wei, W., Ma, L., & Li, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00778 · Cited by 34
Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 40
Vijh, D., Imam, M. A., Haque, M. M. U., Das, S., Islam, A., & Malik, M. Z. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01160-3 · Cited by 32
Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview
Štrac, D. Š., Konjevod, M., Šagud, M., Perković, M. N., Erjavec, G. N., Vuić, B., Šimić, G., Vukić, V., Mimica, N., & Pivac, N. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s284615 · Cited by 30
Bruszt, N., Bali, Z. K., Tadepalli, S. A., Nagy, L. V., & Hernádi, I. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05942-4 · Cited by 29
Treatment of Canine Cognitive Dysfunction With Novel Butyrylcholinesterase Inhibitor
Pipan, M. Z., Mihevc, S. P., Štrbenc, M., Košak, U., Ilić, I. G., Trontelj, J., Žakelj, S., Gobec, S., Pavlin, D., & Majdič, G. (2020) · Scientific Reports · doi:10.1038/s41598-021-97404-2 · Cited by 30
Shi, X., Ren, G., Cui, Y., & Xu, Z. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220120112301 · Cited by 29
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 32
Clare, L., Gamble, L. D., Martyr, A., Sabatini, S., Nelis, S. M., Quinn, C., Pentecost, C., Victor, C. R., Jones, R. W., Jones, I. R., et al. (2022) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbac022 · Cited by 26
Hsu, T., Chu, C., Ching, P., Chen, G., & Pan, C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.047 · Cited by 27
Mitra, S., Gera, R., Linderoth, B., Lind, G., Wahlberg, L. U., Almqvist, P. M., Behbahani, H., & Eriksdotter, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_11 · Cited by 26
Iqbal, D., Rehman, M. T., Alajmi, M. F., Alsaweed, M., Jamal, Q. M. S., Alasiry, S. M., Albaker, A. B., Hamed, M., Kamal, M., & Albadrani, H. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040622 · Cited by 25
Golan, S., Boccara, E., Ravona‐Springer, R., Inbar, Y., Zelicha, H., Livny, A., Bendlin, B. B., Lesman‐Segev, O. H., Yore, I., Heymann, A. D., et al. (2024) · Obesity · doi:10.1002/oby.24004 · Cited by 20
Shiue, Y., Tseng, P., Zeng, B., Chen, Y., Yang, C., Su, K., Chen, T., Wu, Y., Tu, Y., Lin, P., et al. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220420122322 · Cited by 21
Clinical guidelines «Cognitive disorders in the elderly and senile persons»
Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 22
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer’s Disease Treatment
Knight, E., Geetha, T., Broderick, T. L., & Babu, J. R. (2023) · Metabolites · doi:10.3390/metabo13030438 · Cited by 20
Pereira, G. R. C., Gonçalves, L. M., Abrahim-Vieira, B. D. A., & Mesquita, J. F. D. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30277 · Cited by 19
Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil)
Sridhar, G. R. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_418-1 · Cited by 19
Gugliandolo, A., Blando, S., Salamone, S., Caprioglio, D., Pollastro, F., Mazzon, E., & Chiricosta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076598 · Cited by 18
Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Rosa, P., Tata, A. M., Fabrizi, E., Locuratolo, N., Vanacore, N., Lacorte, E., et al. (2024) · Cells · doi:10.3390/cells13030237 · Cited by 20
Tanshinones and their Derivatives: Heterocyclic Ring-Fused Diterpenes of Biological Interest
Estolano-Cobián, A., Macías-Alonso, M., Díaz-Rubio, L., Ponce, C. N., Córdova‐Guerrero, I., & Marrero, J. G. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200429103225 · Cited by 16
Zeng, X., Sheng, Z., Zhang, Y., Xiao, J., Li, Y., Jiaping, Z., Xu, G., Jia, J., Wang, M., & Li, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177098 · Cited by 15
Hanumanthappa, R., Parthasarathy, A., Heggannavar, G. B., Kiran, P. C., Nanjaiah, H., Kumbhar, R., & Devaraju, K. S. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.60 · Cited by 15
Marcolini, S., Frentz, I., Sánchez-Catasús, C. A., Mondragón, J. D., Feltes, P. K., van der Hoorn, A., Borra, R., Ikram, M. A., Dierckx, R., & Deyn, P. P. D. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101661 · Cited by 16
Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials
Brenowitz, W. D., & Yaffe, K. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00733-7 · Cited by 16
The Israel Registry for Alzheimer’s Prevention (IRAP) Study: Design and Baseline Characteristics
Ravona‐Springer, R., Sharvit‐Ginon, I., Ganmore, I., Greenbaum, L., Bendlin, B. B., Sternberg, S. A., Livny, A., Domachevsky, L., Sandler, I., Ben‐Haim, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200623 · Cited by 16
Hanoğlu, L., Velioğlu, H. A., Hanoğlu, T., & Yuluğ, B. (2021) · Clinical EEG and Neuroscience · doi:10.1177/15500594211052815 · Cited by 14
Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil)
Sridhar, G. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_418 · Cited by 17
Tambunan, E. H., & Simbolon, I. (2023) · Journal of Caring Sciences · doi:10.34172/jcs.2023.33098 · Cited by 14
Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
Möllers, T., Perna, L., Stocker, H. R., Ihle, P., Schübert, I., Schöttker, B., Frölich, L., Bauer, J. M., & Brenner, H. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000702 · Cited by 15
CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia
Herrmann, N., Ismail, Z., Collins, R. L., Desmarais, P., Goodarzi, Z., Henri‐Bhargava, A., Iaboni, A., Kirkham, J. G., Massoud, F., Moser, A. L., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12099 · Cited by 12
Möllers, T., Stocker, H. R., Perna, L., Rujescu, D., Holleczek, B., Schöttker, B., & Brenner, H. (2022) · Age and Ageing · doi:10.1093/ageing/afac113 · Cited by 14
Coker-Ayo, O. O., Nathaniel, S. I., Poupore, N. S., Bailey-Taylor, M. J., Roley, L. T., Goodwin, R. L., McPhail, B. T., Russ‐Sellers, R., & Nathaniel, T. I. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.828782 · Cited by 13
Dynamic distribution of gut microbiota during Alzheimer's disease progression in a mice model
Zhu, J., Liu, S., Zhang, H., Zhao, W., Ding, J., Dai, R., Xu, K., He, C., Liu, J., Yang, L., et al. (2023) · Apmis · doi:10.1111/apm.13339 · Cited by 14
Posadas, Y., Parra-Ojeda, L., Perez‐Cruz, C., & Quintanar, L. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c00846 · Cited by 14
Recent advances in diagnostic and therapeutic strategies for canine cognitive dysfunction
Kim, S. H., & Hao, J. (2025) · American Journal of Veterinary Research · doi:10.2460/ajvr.25.02.0053 · Cited by 14
New use of psychotropic medication after hospitalization among people with dementia
Möllers, T., Perna, L., Stocker, H. R., Ihle, P., Schübert, I., Schöttker, B., Frölich, L., & Brenner, H. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5282 · Cited by 13
Takramah, W. K., & Asem, L. (2022) · Health Science Reports · doi:10.1002/hsr2.913 · Cited by 13
Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil
Price, P. U., Heggie, R., Moriguti, J. C., & Pereira, L. R. L. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2025.101130 · Cited by 11
Liu, S., Min, Z., Liu, Y., Yang, X., Yan, H., Xu, H. E., Wu, Y., & Xu, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1656906 · Cited by 12
Antidementia Medication Use in Nursing Home Residents
Ott, B. R., Hollins, C., Tjia, J., Baek, J., Chen, Q., Lapane, K. L., & Alcusky, M. J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231202948 · Cited by 10
Jia, J., Ji, Y., Feng, T., Ye, Q., Peng, D., Kuang, W., Ning, Y., Liang, Z., Fan, D., Wei, W., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190791 · Cited by 9
Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis protocol
Huang, Y., Dou, K., Zhong, X.-L., Shen, X., Chen, S.-D., Li, H., Chen, K., Cui, M., Dong, Q., Tan, L., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-611 · Cited by 7
Self-citationCao, Y., Liang, Q., Yu, W., Li, T., Mao, S., & Han, G. (2020) · Journal of International Medical Research · doi:10.1177/0300060520902895 · Cited by 9
Herr, M., Ankri, J., Diard, C., & Hiance‐Delahaye, A. (2021) · Drugs & Aging · doi:10.1007/s40266-020-00817-3 · Cited by 8
Li, B., Wu, Y.-R., Li, L., Liu, Y., & Yan, Z. (2022) · Molecules · doi:10.3390/molecules27144463 · Cited by 8
Yoon, E., Ahn, J. W., Kim, H.-S., Choi, Y., Jeong, J., Joo, S. S., & Park, D. (2023) · Nutrients · doi:10.3390/nu15153389 · Cited by 8
Mediterranean Shrub Species as a Source of Biomolecules against Neurodegenerative Diseases
Chaves, N., Nogales, L., Fernández, I. M., Salas, J. B., & Alías, J. C. (2023) · Molecules · doi:10.3390/molecules28248133 · Cited by 8
Minuti, A., Mazzon, E., Iori, R., Chiricosta, L., & Artimagnella, O. (2024) · Nutrients · doi:10.3390/nu16234202 · Cited by 9
Curcumin effect on non-amyloidogenic pathway for preventing Alzheimer’s disease
(2019) · Biointerface Research in Applied Chemistry · doi:10.33263/briac94.085089 · Cited by 8
Chiricosta, L., Minuti, A., Gugliandolo, A., Salamone, S., Pollastro, F., Mazzon, E., & Artimagnella, O. (2024) · Cells · doi:10.3390/cells13121012 · Cited by 7
Memantine: updates from the past decade and implications for future novel therapeutic applications
Danysz, W., Hansen, N., Wiltfang, J., Kornhuber, J., Scheschonka, A., & Gravius, A. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03017-8 · Cited by 7
Morte, A., Vaqué, A., Iniesta, M., Schug, B. S., Koch, C., de la Torre, R., & Schurad, B. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00778-5 · Cited by 7
Zidan, E. F., El-Mezayen, N. S., El‐Rewini, S. H., Afify, E. A., & Ali, M. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10159-1 · Cited by 7
Rapid health technology assessment of galantamine for the treatment of Alzheimer’s disease: A review
Xing, B., Yang, J., Hua, H., & Jiang, R. (2025) · Medicine · doi:10.1097/md.0000000000042744 · Cited by 7
Fortea, J., & Ferrer-Picón, E. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2527211 · Cited by 6
Özge, A., Ghouri, R., Öksüz, N., & Taşdelen, B. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1240655 · Cited by 6
AChEI-EL:Prediction of Acetylcholinesterase Inhibitors Based on Ensemble Learning Model
Wang, Z., Sun, D., Jiang, S., & Huang, W. C. (2022) · IEEE International Conference on Big Data Analytics (ICBDA) · doi:10.1109/icbda55095.2022.9760329 · Cited by 6
Gender Differences in the Effects of Exercise Interventions on Alzheimer’s Disease
Dong, Y., Shi, L., Ma, Y., Liu, Y., Sun, Y., & Jin, Q. (2025) · Brain Sciences · doi:10.3390/brainsci15080812 · Cited by 9
Almalki, S. G., Alqurashi, Y. E., Alturaiki, W., Almawash, S., Khan, A., Ahmad, P., & Iqbal, D. (2023) · Biomolecules · doi:10.3390/biom13101474 · Cited by 5
Bhosale, S. S., Sivakkumar, S., Jamadagni, S. B., & Arulmozhi, S. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00086 · Cited by 5
Merighi, S., Nigro, M., Travagli, A., Fernández, M., Vincenzi, F., Varani, K., Pasquini, S., Borea, P. A., Salati, S., Cadossi, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312847 · Cited by 6
Treatment of Vascular and Neurodegenerative Forms of Cognitive Impairment and Dementias
Perlett, L., & Smith, E. E. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.008 · Cited by 5
Chintalapati, M., & Margesan, T. (2024) · Future Science OA · doi:10.2144/fsoa-2023-0255 · Cited by 9
Zhou, H., Yao, W., Shan, Q., Zhang, X., Zhang, D., Che, J., & Bai, F. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.113322 · Cited by 5
Neuroprotection in Alzheimer Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_8 · Cited by 5
Tolerability of memantine monotherapy versus adding memantine as combination therapy
Isaac, E., Ney, D., Serruya, M. D., Keith, S., Lippa, C. F., & Sperling, M. R. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.02.006 · Cited by 5
Metadata
- Authors
- Dou, K.-X., Tan, M.-S., Tan, C.-C., Cao, X.-P., Hou, X.-H., Guo, Q.-H., Tan, L., Mok, V., & Yu, J.-T.
- Affiliations
- Qingdao University (CN)
- Fudan University (CN)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Tan, Lan
- Yu, Jin-Tai
- Venue
- Alzheimer's Research & Therapy
- Published
- 2018-12
- Volume
- 10
- Issue
- 1
- Pages
- 126-126
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC6309083
- OpenAlex
- W2907817008
- Cited by
- 171
- References
- 41
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 24 · 2023: 31 · 2022: 28 · 2021: 22 · 2020: 16 · 2019: 11
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, memantine, galantamine, donepezil, rivastigmine, cognitive function, drug efficacy, drug safety, tolerability, neuropsychiatric symptoms, disease severity, combination therapy
- MeSH terms
- Network Meta-Analysis, Alzheimer Disease, Cholinesterase Inhibitors, Female, Humans, Male, Memantine, Randomized Controlled Trials as Topic, Treatment Outcome, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
